Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Lawson

Showing results (71-80 of 128) with videos related to

Pageof 13
Sort By:
Biochemical and Biophysical Research Communications|May 24, 2017
Identification of AHCY inhibitors using novel high-throughput mass spectrometryNoriko Uchiyama, Douglas R Dougan, J David Lawson, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|April 30, 2002
Long-term clinical outcome after implantation of medium Palmaz (biliary) stents in very large native coronary arteriesFrancisco L Chio, Ming W Liu, Shukri M Al-Saif, et al.
Disability and Rehabilitation|February 13, 2024
Development of the Valued Living Questionnaire - Comprehension Support version (VLQ-CS) and validation in adults with acquired brain injuryDana Wong, Hannah Miller, David Lawson, et al.
Thescientificworldjournal|July 6, 2018
The Protein Trinity: Structure/Function Relationships That Include Intrinsic DisorderA Keith Dunker, Celeste J Brown, Celeste J David Lawson, et al.
Bioorganic & Medicinal Chemistry Letters|April 1, 2017
Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitorsMark Sabat, Haixia Wang, Nick Scorah, et al.
Bioorganic & Medicinal Chemistry Letters|July 28, 2016
Design, synthesis and optimization of novel Alk5 (activin-like kinase 5) inhibitorsHaixia Wang, J David Lawson, Nick Scorah, et al.
Investigational New Drugs|October 16, 2009
A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanomaKarl D Lewis, Wolfram Samlowski, John Ward, et al.
Biochemical and Biophysical Research Communications|June 12, 2010
Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesisMohammad H Pourgholami, Levon M Khachigian, Roger G Fahmy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanomaSteven O'Day, Rene Gonzalez, David Lawson, et al.
Protein Science : a Publication of the Protein Society|December 24, 2003
Protein flexibility and intrinsic disorderPredrag Radivojac, Zoran Obradovic, David K Smith, et al.
Pageof 13

Showing results (71-80 of 128) with videos related to

Sort By:
Pageof 13
Biochemical and Biophysical Research Communications|May 24, 2017
Identification of AHCY inhibitors using novel high-throughput mass spectrometryNoriko Uchiyama, Douglas R Dougan, J David Lawson, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|April 30, 2002
Long-term clinical outcome after implantation of medium Palmaz (biliary) stents in very large native coronary arteriesFrancisco L Chio, Ming W Liu, Shukri M Al-Saif, et al.
Disability and Rehabilitation|February 13, 2024
Development of the Valued Living Questionnaire - Comprehension Support version (VLQ-CS) and validation in adults with acquired brain injuryDana Wong, Hannah Miller, David Lawson, et al.
Thescientificworldjournal|July 6, 2018
The Protein Trinity: Structure/Function Relationships That Include Intrinsic DisorderA Keith Dunker, Celeste J Brown, Celeste J David Lawson, et al.
Bioorganic & Medicinal Chemistry Letters|April 1, 2017
Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitorsMark Sabat, Haixia Wang, Nick Scorah, et al.
Bioorganic & Medicinal Chemistry Letters|July 28, 2016
Design, synthesis and optimization of novel Alk5 (activin-like kinase 5) inhibitorsHaixia Wang, J David Lawson, Nick Scorah, et al.
Investigational New Drugs|October 16, 2009
A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanomaKarl D Lewis, Wolfram Samlowski, John Ward, et al.
Biochemical and Biophysical Research Communications|June 12, 2010
Albendazole inhibits endothelial cell migration, tube formation, vasopermeability, VEGF receptor-2 expression and suppresses retinal neovascularization in ROP model of angiogenesisMohammad H Pourgholami, Levon M Khachigian, Roger G Fahmy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 15, 2009
Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanomaSteven O'Day, Rene Gonzalez, David Lawson, et al.
Protein Science : a Publication of the Protein Society|December 24, 2003
Protein flexibility and intrinsic disorderPredrag Radivojac, Zoran Obradovic, David K Smith, et al.
Pageof 13